Search

Your search keyword '"Felker, G"' showing total 2,347 results
Start Over Author "Felker, G"
2,347 results on '"Felker, G"'

151. Prognostic Implications of Long-Chain Acylcarnitines in Heart Failure and Reversibility With Mechanical Circulatory Support

Author

Ahmad, Tariq, Kelly, Jacob P., McGarrah, Robert W., Hellkamp, Anne S., Fiuzat, Mona, Testani, Jeffrey M., Wang, Teresa S., Verma, Amanda, Samsky, Marc D., Donahue, Mark P., Ilkayeva, Olga R., Bowles, Dawn E., Patel, Chetan B., Milano, Carmelo A., Rogers, Joseph G., Felker, G. Michael, O’Connor, Christopher M., Shah, Svati H., and Kraus, William E.

Published
2016
Full Text
View/download PDF

156. Prognostic Impact of Repeated NT-proBNP Measurements in Patients With Heart Failure With Reduced Ejection Fraction

Author

Fuery, Michael A., Leifer, Eric S., Samsky, Marc D., Sen, Sounok, O’Connor, Christopher M., Fiuzat, Mona, Ezekowitz, Justin, Piña, Ileana, Whellan, David, Mark, Daniel, Felker, G. Michael, Desai, Nihar R., Januzzi, James L., and Ahmad, Tariq

Abstract

Although clinical studies have demonstrated the association between a single N-terminal pro–B-type natriuretic peptide (NT-proBNP) measurement and clinical outcomes in chronic heart failure, the biomarker is frequently measured serially in clinical practice.

Published
2024
Full Text
View/download PDF

158. Impact of vasodilators on diuretic response in patients with congestive heart failure: A mechanistic trial of cimlanod (BMS‐986231).

Author

Pellicori, Pierpaolo, Cleland, John G.F., Borentain, Maria, Taubel, Jorg, Graham, Fraser J., Khan, Javed, Bruzzese, Dario, Kessler, Paul, McMurray, John J.V., Voors, Adriaan A., O'Connor, Christopher M., Teerlink, John R., and Felker, G. Michael

Subjects
FUROSEMIDE, BRAIN natriuretic factor, CONGESTIVE heart failure, HEART failure patients, SYSTOLIC blood pressure, DIURETICS
Abstract

Aim: To investigate the effects of Cimlanod, a nitroxyl donor with vasodilator properties, on water and salt excretion after an administration of an intravenos bolus of furosemide. Methods and results: In this randomized, double‐blind, mechanistic, crossover trial, 21 patients with left ventricular ejection fraction <45%, increased plasma concentrations of N‐terminal pro‐B‐type natriuretic peptide (NT‐proBNP) and receiving loop diuretics were given, on separate study days, either an 8 h intravenous (IV) infusion of cimlanod (12 μg/kg/min) or placebo. Furosemide was given as a 40 mg IV bolus four hours after the start of infusion. The primary endpoint was urine volume in the 4 h after the bolus of furosemide during infusion of cimlanod compared with placebo. Median NT‐proBNP at baseline was 1487 (interquartile range: 847–2665) ng/L. Infusion of cimlanod increased cardiac output and reduced blood pressure without affecting cardiac power index consistent with its vasodilator effects. Urine volume in the 4 h post‐furosemide was lower with cimlanod (1032 ± 393 ml) versus placebo (1481 ± 560 ml) (p = 0.002), as were total sodium excretion (p = 0.004), fractional sodium excretion (p = 0.016), systolic blood pressure (p < 0.001), estimated glomerular filtration rate (p = 0.012), and haemoglobin (p = 0.010), an index of plasma volume expansion. Conclusions: For patients with heart failure and congestion, vasodilatation with agents such as cimlanod reduces the response to diuretic agents, which may offset any benefit from acute reductions in cardiac preload and afterload. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

159. Natriuretic peptides: role in the diagnosis and management of heart failure: a scientific statement from the Heart Failure Association of the European Society of Cardiology, Heart Failure Society of America and Japanese Heart Failure Society

Author

Tsutsui, Hiroyuki, primary, Albert, Nancy M., additional, Coats, Andrew J.S., additional, Anker, Stefan D., additional, Bayes‐Genis, Antoni, additional, Butler, Javed, additional, Chioncel, Ovidiu, additional, Defilippi, Christopher R., additional, Drazner, Mark H., additional, Felker, G. Michael, additional, Filippatos, Gerasimos, additional, Fiuzat, Mona, additional, Ide, Tomomi, additional, Januzzi, James L., additional, Kinugawa, Koichiro, additional, Kuwahara, Koichiro, additional, Matsue, Yuya, additional, Mentz, Robert J., additional, Metra, Marco, additional, Pandey, Ambarish, additional, Rosano, Giuseppe, additional, Saito, Yoshihiko, additional, Sakata, Yasushi, additional, Sato, Naoki, additional, Seferovic, Petar M., additional, Teerlink, John, additional, Yamamoto, Kazuhiro, additional, and Yoshimura, Michihiro, additional

Published
2023
Full Text
View/download PDF

161. Polypharmacy and Optimization of Guideline-Directed Medical Therapy in Heart Failure

Author

Khan, Muhammad Shahzeb, primary, Singh, Sumitabh, additional, Segar, Matthew W., additional, Usman, Muhammad Shariq, additional, Keshvani, Neil, additional, Ambrosy, Andrew P., additional, Fiuzat, Mona, additional, Van Spall, Harriette G.C., additional, Fonarow, Gregg C., additional, Zannad, Faiez, additional, Felker, G. Michael, additional, Januzzi, James L., additional, O’Connor, Christopher, additional, Butler, Javed, additional, and Pandey, Ambarish, additional

Published
2023
Full Text
View/download PDF

163. Splanchnic Nerve Block with Botulinum Toxin for Therapy of Chronic Heart Failure ‐ Mechanism of Action (SPONGE‐HF)

Author

Fudim, Marat, primary, Parikh, Kishan, additional, Ganesh, Arun, additional, Molinger, Jeroen, additional, Ray, Neil, additional, Coburn, Aubrie, additional, Coyne, Brian J., additional, Swavely, Ashley G., additional, Andrews, Jennifer, additional, Gray, James Matthew, additional, Rao, Vishal N., additional, Felker, G. Michael, additional, Borges‐Neto, Salvador, additional, Hernandez, Adrian F., additional, and Patel, Manesh R., additional

Published
2023
Full Text
View/download PDF

165. Impact of mitral regurgitation in patients with acute heart failure: insights from the RELAX‐AHF ‐2 trial

Author

Pagnesi, Matteo, primary, Adamo, Marianna, additional, ter Maaten, Jozine M., additional, Beldhuis, Iris E., additional, Cotter, Gad, additional, Davison, Beth A., additional, Felker, G. Michael, additional, Filippatos, Gerasimos, additional, Greenberg, Barry H., additional, Pang, Peter S., additional, Ponikowski, Piotr, additional, Sama, Iziah E., additional, Severin, Thomas, additional, Gimpelewicz, Claudio, additional, Voors, Adriaan A., additional, Teerlink, John R., additional, and Metra, Marco, additional

Published
2023
Full Text
View/download PDF

166. WHAT IS THE VALUE OF REPEATED NT-PROBNP MEASUREMENTS IN CHRONIC HEART FAILURE WITH REDUCED EJECTION FRACTION?

Author

Fuery, Michael A., primary, Leifer, Eric, additional, Samsky, Marc, additional, Sen, Sounok, additional, O'Connor, Christopher M., additional, Fiuzat, Mona, additional, Ezekowitz, Justin A., additional, Pina, Ileana L., additional, Whellan, David J., additional, Mark, Daniel B., additional, Felker, G. Michael, additional, Desai, Nihar R., additional, Januzzi, James L., additional, and Ahmad, Tariq, additional

Published
2023
Full Text
View/download PDF

168. APPLICABILITY OF THE GALACTIC-HF TRIAL AND OMECAMTIV MECARBIL TO PATIENTS HOSPITALIZED FOR HEART FAILURE IN THE UNITED STATES: FROM THE GWTG-HF REGISTRY

Author

Harrington, Josephine, primary, Sun, Jie, additional, Fonarow, Gregg C., additional, Heitner, Stephen B., additional, Divanji, Punag, additional, Alhanti, Brooke, additional, Allen, Larry A., additional, Yancy, Clyde W., additional, Albert, Nancy M., additional, DeVore, Adam, additional, Felker, G. Michael, additional, and Greene, Stephen, additional

Published
2023
Full Text
View/download PDF

171. ADJUSTMENT OF GUIDELINE-DIRECTED MEDICAL THERAPY ONE YEAR POST-HEART FAILURE HOSPITALIZATION FALLS SHORT: INSIGHTS FROM THE CONNECT-HF TRIAL

Author

Chapman, Brittany, primary, Kaltenbach, Lisa, additional, Granger, Bradi, additional, Allen, Larry A., additional, Albert, Nancy M., additional, Al-Khalidi, Hussein, additional, Granger, Christopher B., additional, Lanfear, David E., additional, Thibodeau, Jennifer T., additional, Oliver-McNeil, Sandra M., additional, Butler, Javed, additional, Felker, G. Michael, additional, Pina, Ileana L., additional, Fonarow, Gregg C., additional, Hernandez, Adrian F., additional, and DeVore, Adam, additional

Published
2023
Full Text
View/download PDF

173. Circulating Kidney Injury Molecule-1 Levels in Acute Heart Failure: Insights From the ASCEND-HF Trial (Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure)

Author

Grodin, Justin L., Perez, Antonio L., Wu, Yuping, Hernandez, Adrian F., Butler, Javed, Metra, Marco, Felker, G. Michael, Voors, Adriaan A., McMurray, John J., Armstrong, Paul W., Califf, Robert M., Starling, Randall C., O'Connor, Christopher M., and Tang, W.H. Wilson

Published
2015
Full Text
View/download PDF

178. Heart Failure Therapeutics on the Basis of a Biased Ligand of the Angiotensin-2 Type 1 Receptor: Rationale and Design of the BLAST-AHF Study (Biased Ligand of the Angiotensin Receptor Study in Acute Heart Failure)

Author

Felker, G. Michael, Butler, Javed, Collins, Sean P., Cotter, Gad, Davison, Beth A., Ezekowitz, Justin A., Filippatos, Gerasimos, Levy, Phillip D., Metra, Marco, Ponikowski, Piotr, Soergel, David G., Teerlink, John R., Violin, Jonathan D., Voors, Adriaan A., and Pang, Peter S.

Published
2015
Full Text
View/download PDF

180. Relationship between baseline systolic blood pressure and long-term outcomes in acute heart failure patients treated with TRV027: an exploratory subgroup analysis of BLAST-AHF

Author

Cotter, Gad, Davison, Beth A., Butler, Javed, Collins, Sean P., Ezekowitz, Justin A., Felker, G. Michael, Filippatos, Gerasimos, Levy, Phillip D., Metra, Marco, Ponikowski, Piotr, Teerlink, John R., Voors, Adriaan A., Senger, Stefanie, Bharucha, David, Goin, Kathleen, Soergel, David G., and Pang, Peter S.

Published
2017
Full Text
View/download PDF

181. Comparative Assessment of Short-Term Adverse Events in Acute Heart Failure With Cystatin C and Other Estimates of Renal Function: Results From the ASCEND-HF Trial

Author

Tang, W.H. Wilson, Dupont, Matthias, Hernandez, Adrian F., Voors, Adriaan A., Hsu, Amy P., Felker, G. Michael, Butler, Javed, Metra, Marco, Anker, Stefan D., Troughton, Richard W., Gottlieb, Stephen S., McMurray, John J., Armstrong, Paul W., Massie, Barry M., Califf, Robert M., O’Connor, Christopher M., and Starling, Randall C.

Published
2015
Full Text
View/download PDF

183. Efficacy of omecamtiv mecarbil in heart failure with reduced ejection fraction according to N‐terminal pro‐B‐type natriuretic peptide level: insights from the GALACTIC‐HF trial

Author

Docherty, Kieran F., primary, McMurray, John J.V., additional, Claggett, Brian L., additional, Miao, Zi Michael, additional, Adams, Kirkwood F., additional, Arias‐Mendoza, Alexandra, additional, Cleland, John G.F., additional, Diaz, Rafael, additional, Echeverria Correa, Luis E, additional, Felker, G. Michael, additional, Fonseca, Candida, additional, Li, Jing, additional, Metra, Marco, additional, Sliwa‐Hahnle, Karen, additional, Solomon, Scott D., additional, Vandekerckhove, Hans J., additional, Vinereanu, Dragos, additional, Voors, Adriaan A., additional, Heitner, Stephen B., additional, Kupfer, Stuart, additional, Malik, Fady I., additional, Meng, Lisa, additional, and Teerlink, John R., additional

Published
2023
Full Text
View/download PDF

184. Efficacy of omecamtiv mecarbil in heart failure with reduced ejection fraction according to N-terminal pro-B-type natriuretic peptide level: Insights from the GALACTIC-HF trial

Author

Docherty, Kieran F, Mcmurray, John J V, Claggett, Brian L, Miao, Zi Michael, Adams, Kirkwood F, Arias-Mendoza, Alexandra, Cleland, John G F, Diaz, Rafael, Echeverria Correa, Luis E, Felker, G Michael, Fonseca, Candida, Li, WEN JING, Metra, Marco, Sliwa-Hahnle, Karen, Solomon, Scott D, Vandekerckhove, Hans J, Vinereanu, Dragos, Voors, Adriaan A, Heitner, Stephen B, Kupfer, Stuart, Malik, Fady I, Meng, Lisa, and Teerlink, John R

Subjects
Pharmacology, Treatment, Calcium cycling/excitation-contraction coupling, Mortality/survival, Heart failure, Acute coronary syndromes, Cardiology and Cardiovascular Medicine, Atrial fibrillation
Abstract

N-terminal pro-B-type natriuretic peptide (NT-proBNP) is predictive of both outcomes and response to treatment in patients with heart failure with reduced ejection fraction (HFrEF).To examine the effect of the cardiac myosin activator omecamtiv mecarbil according to baseline NT-proBNP level in the Global Approach to Lowering Adverse Cardiac outcomes Through Improving Contractility in Heart Failure trial (GALACTIC-HF).The primary outcome was the composite of a worsening HF event (urgent clinic visit, emergency department visit, or hospitalization) or cardiovascular death. We prespecified analysis of the effect of treatment according to baseline NT-proBNP (≤median,median), excluding individuals with AF/AFL.Of the 8232 patients analyzed, 8206 had an available baseline NT-proBNP measurement. Among the 5971 patients not in AF/AFL, the median (Q1, Q3) NT-proBNP level was 1675 (812-3579) pg/ml. Hazard ratios (HR) for the effect of omecamtiv mecarbil, compared with placebo, for the primary endpoint in patients without AF/AFL were: ≤median 0.94 (95% CI, 0.80-1.09),median 0.81 (0.73-0.90) [P-interaction = 0.095]; for the overall population (including patients with AF/AFL) the HRs were ≤ median 1.01 (0.90-1.15) and median 0.88 (0.80-0.96) [P-interaction = 0.035]. There was an interaction between treatment and NT-proBNP, examined as a continuous variable, with greater effect of omecamtiv mecarbil on the primary outcome in patients with a higher baseline NT-proBNP (P-interaction = 0.086).In GALACTIC-HF, the benefit of omecamtiv mecarbil appeared to be larger in patients with higher baseline NT-proBNP levels, especially in patients without AF/AFL. This article is protected by copyright. All rights reserved.

Published
2022

185. Fluvoxamine for Outpatient Treatment of COVID-19: A Decentralized, Placebo-controlled, Randomized, Platform Clinical Trial

Author

McCarthy, Matthew W., Naggie, Susanna, Boulware, David R., Lindsell, Christopher J., Stewart, Thomas G., Felker, G. Michael, Jayaweera, Dushyantha, Sulkowski, Mark, Gentile, Nina, Bramante, Carolyn, Singh, Upinder, Dolor, Rowena J., Ruiz-Unger, Juan, Wilson, Sybil, DeLong, Allison, Remaly, April, Wilder, Rhonda, Collins, Sean, Dunsmore, Sarah E., Adam, Stacey J., Thicklin, Florence, Hanna, George, Ginde, Adit A., Castro, Mario, McTigue, Kathleen, Shenkman, Elizabeth, and Hernandez, Adrian F.

Subjects
Article
Abstract

BackgroundThe effectiveness of fluvoxamine to shorten symptom duration or prevent hospitalization among outpatients in the US with mild to moderate symptomatic coronavirus disease 2019 (COVID-19) is unclear.DesignACTIV-6 is an ongoing, decentralized, double-blind, randomized, placebo-controlled platform trial testing repurposed medications in outpatients with mild to moderate COVID-19. A total of 1288 non-hospitalized adults aged ≥30 years with confirmed COVID-19 experiencing ≥2 symptoms of acute infection for ≤7 days prior to randomization were randomized to receive fluvoxamine 50 mg or placebo twice daily for 10 days. The primary outcome was time to sustained recovery, defined as the third of 3 consecutive days without symptoms. Secondary outcomes included composites of hospitalization or death with or without urgent or emergency care visit by day 28.ResultsOf 1331 participants randomized (mean [SD] age, 48.5 [12.8] years; 57% women; 67% reported receiving at least 2 doses of a SARS-CoV-2 vaccine), 1288 completed the trial (n=614 placebo, n=674 fluvoxamine). Median time to recovery was 13 days (IQR 12–13) in the placebo group and 12 days (IQR 11–14) in the fluvoxamine group (hazard ratio [HR] 0.96, 95% credible interval [CrI] 0.86–1.07; posterior probability for benefit [HR>1]=0.22). Twenty-six participants (3.9%) in the fluvoxamine group were hospitalized or had urgent or emergency care visits compared with 23 (3.8%) in the placebo group (HR 1.1, 95% CrI 0.6–1.8; posterior probability for benefit [HRConclusionsTreatment with fluvoxamine 50 mg twice daily for 10 days did not improve time to recovery, compared with placebo, among outpatients with mild to moderate COVID-19. These findings do not support the use of fluvoxamine at this dose and duration in patients with mild to moderate COVID-19.

Published
2022

186. Association Between Sacubitril/Valsartan Initiation and Mitral Regurgitation Severity in Heart Failure With Reduced Ejection Fraction: The PROVE-HF Study

Author

Januzzi, James L., primary, Omar, Alaa Mabrouk Salem, additional, Liu, Yuxi, additional, Murphy, Sean, additional, Butler, Javed, additional, Felker, G. Michael, additional, Piña, Iliana L., additional, Ward, Jonathan, additional, Solomon, Scott, additional, and Contreras, Johanna, additional

Published
2022
Full Text
View/download PDF

190. Rationale and Design of the GUIDE-IT Study: Guiding Evidence Based Therapy Using Biomarker Intensified Treatment in Heart Failure

Author

Felker, G. Michael, Ahmad, Tariq, Anstrom, Kevin J., Adams, Kirkwood F., Cooper, Lawton S., Ezekowitz, Justin A., Fiuzat, Mona, Houston-Miller, Nancy, Januzzi, James L., Leifer, Eric S., Mark, Daniel B., Desvigne-Nickens, Patrice, Paynter, Gayle, Piña, Ileana L., Whellan, David J., and O’Connor, Christopher M.

Published
2014
Full Text
View/download PDF

199. Contributors

Author

Abbara, Suhny, primary, Aguilar, David, additional, Awtry, Eric H., additional, Baez-Escudero, Jose L., additional, Bakaeen, Faisal, additional, Balady, Gary J., additional, Beauchesne, Luc M., additional, Bernard, Sheilah A., additional, Bilen, Ozlem, additional, Birnbaum, Itamar, additional, Birnbaum, Yochai, additional, Boccalandro, Fernando, additional, Bozkurt, Biykem, additional, Carabello, Blase, additional, Chandrasekhar, Jaya, additional, Cooper, Leslie T., additional, Cunningham, Luke, additional, Denktas, Ali E., additional, Deswal, Anita, additional, Elgharably, Haytham, additional, Faber, Lothar, additional, Farkouh, Michael E., additional, Faza, Nadeen N., additional, Fedson, Savitri, additional, Felker, G. Michael, additional, Fenton, James J., additional, Field, Michael E., additional, Flamm, Scott D., additional, Fleisher, Lee A., additional, Flink, Laura Epstein, additional, French, Amy, additional, Fudim, Marat, additional, Gannon, Stephen A., additional, Governatori, Nicholas, additional, Grines, Cindy, additional, Habib, Gabriel B., additional, Hamzeh, Ihab, additional, Hinohara, Tomoya Timothy, additional, Hoang, Vu, additional, Hoit, Brian D., additional, Jneid, Hani, additional, Joglar, Jose A., additional, Johnston, Douglas R., additional, Joseph, Lee, additional, Kayani, Waleed T., additional, Kent, Thomas A., additional, Kerrigan, Jimmy L., additional, Kfoury, Elias, additional, Khalaf, Shaden, additional, Khalid, Mirza Umair, additional, Kim, Esther S.H., additional, Kougias, Panos, additional, Krishnaswamy, Amar, additional, Kroll, Michael H., additional, Kulkarni, Nitin, additional, Lange, Richard A., additional, Mangione, Salvatore, additional, Martini, Sharyl R., additional, McCord, James, additional, Mehran, Roxana, additional, Merli, Geno J., additional, Mick, Stephanie L., additional, Moore, Curtiss, additional, Nair, Ajith, additional, Nambi, Vijay, additional, Nicewarner, Heidi, additional, Ohman, E. Magnus, additional, Palaskas, Nicolas, additional, Pandit, Lavannya M., additional, Patel, Niraj R., additional, Phillips, Lawrence, additional, Pipe, Andrew, additional, Pollack, Charles V., additional, Pollet, Mark, additional, Prenner, Stuart B., additional, Rajiah, Prabhakar, additional, Rodriguez-Manero, Moises, additional, Roselli, Eric E., additional, Safdar, Zeenat, additional, Sanchez-Alvarez, Catalina, additional, Schurmann, Paul, additional, Shah, Nishant R., additional, Shah, Sanjiv J., additional, Shah, Tina, additional, Shaib, Fidaa, additional, Sidhu, Mandeep S., additional, Soltesz, Edward G., additional, Spinler, Sarah A., additional, Sun, Yamin, additional, Tamara, Luis A., additional, Tapson, Victor, additional, Thamwiwat, Alisa, additional, Thavendiranathan, Paaladinesh, additional, Thomas, Rahul, additional, Thompson, Kara A., additional, Titas, Megan, additional, Zhen-Yu Tong, Michael, additional, Valderrábano, Miguel, additional, Vekstein, Andrew, additional, Virani, Salim, additional, Virk, Fawad, additional, Von Schoettler, Hercilia, additional, Weinberg, Aaron S., additional, and Zeeshan, Ahmad, additional

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results